US equities |
NVDA $237.82 ▲+1.65% SPCX $167.85 ▲+5.59% MU $1,063.31 ▼-1.08% TSLA $378.98 ▲+2.26% MSFT $524.80 ▲+1.41% SNDK $1,711.12 ▼-0.52% INTC $116.99 ▼-1.96% META $742.09 ▲+1.92%
FinancialContent

Articles published by Annexon Biosciences

< Previous 1 2 3 4 Next >
News headline image
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
< Previous 1 2 3 4 Next >